Underground psychedelic-assisted psychotherapy has persisted in Europe despite the banning of the substances LSD and MDMA in the 1960s and 1980s, respectively. This article describes the work of a Zurich-based psychotherapist providing individual and group psycholytic psychotherapy, whose practice persisted for several years before she was arrested in 2009. The article provides commentary on the psychopharmacological, moral, ethical and legal issues of this case and discusses these issues in the context of the growing medical research of psychedelic substances as mainstream treatments for psychiatry.
BrunnerDHenR (1997) Insights into the neurobiology of impulsive behavior from serotonin receptor knockout mice. Annals of the New York Academy of Sciences836: 81–105.
2.
CozziNVSievertMKShulginAT (1999) Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. European Journal of Pharmacology381: 63–69.
3.
FitzgeraldJLReidJJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. European Journal of Pharmacology191: 217–220.
4.
Gasser P, Holstein D, Michel Y, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. Journal of Nervous and Mental Disease 202(7): 513–520.
5.
GraeffFGGuimaraesFSDe AndradeTG (1996) Role of 5-HT in stress, anxiety, and depression. Pharmacology, Biochemistry and Behavior54: 129–141.
6.
GreerGTolbertP (1986) Subjective reports on the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs18: 319–332.
7.
GriffithsRRRichardWAMcCannU (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Journal of Psychopharmacology187: 268–283.
8.
GrofS (1980/2001) LSD Psychotherapy, Ben Lomond, CA: Multidisciplinary Association for Psychedelic Studies, pp. .
9.
HofmannA (1980) LSD: My Problem Child, New York: McGraw-Hill, pp. 35–53.
10.
Krebs TS and Johansen P-ؘ (2013) Psychedelics and mental health: A population study. PLoS ONE 8(8): e63972. DOI: 10.1371/journal.pone.0063972.
11.
KruitskyEMBurakovAMDunaevskyIV (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. Journal of Psychoactive Drugs39: 13–19.
12.
LavelleAHonnerVDochertyJR (1999) Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. British Journal of Pharmacology128: 975–980.
13.
MithoeferMCWagnerMTMithoeferAT (2011) The safety and efficacy of {#x0002B;/−}3,4-methylenedioxymethamphetamineassisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology25: 439–452.
14.
MorenoFAWiegandCBTaitanoEK (2006) Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry67(11): 1735–1740.
15.
NashJFRothBLBrodkinJD (1994) Effect of the R(−) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neuroscience Letters177: 111–115.
16.
Nutt DJ, King LA and Nichols DE (2013) Effects of schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience 14: 577–585.
17.
NuttDJKingLAPhillipsLD (2010) Drug harms in the UK: A multicriteria decision analysis. The Lancet376(9752): 1558–1565.
18.
SessaB (2005) Can psychedelics have a role in psychiatry again?British Journal of Psychiatry186: 457–458.
19.
SessaB (2007) Is there a case for MDMA-Assisted Psychotherapy in the UK?Journal of Psychopharmacology21: 220–221.
20.
SessaB (2011) Could MDMA be useful in the treatment of post-traumatic stress disorder?Progress in Neurology and Psychiatry15(6): 4–7.
21.
SessaB (2012) The Psychedelic Renaissance: Reassessing the Role of Psychedelic Drugs in 21st Century Psychiatry and Society, London: Muswell Hill Press.
22.
Sessa B and Nutt DJ (2015) Making a medicine out of MDMA. British Journal of Psychiatry 206(1): 4–6.
23.
StrassmanRJ (1995) Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltrptamine in human. Biological Psychiatry39: 784–795.
24.
ThompsonMRCallaghanPDHuntPD (2007) A role for oxytocin and 5HT(1A) receptors in the prosocial effects of 3,4, methylenedioxyamphetamine (“ecstasy”). Neuroscience146(2): 509–514.
